SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$1.8B
Q2 2020
Positions
56
Filings on Record
24
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Endurant Capital Management LP reported $1.8B in U.S.-listed holdings across 56 positions for Q2 2020.

Compared with Q1 2020, the fund opened 25 new positions and exited 20.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Top-10 Concentration
+6.2%
share of reported value
Largest Position
+1.0%
Oxford Immunotec Global
New / Exited
25 / 20
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
ETP: 86.6%Common Stock: 9.4%Other: 2.4%US DOMESTIC: 1.0%ADR: 0.5%
  • ETP · 86.6% · $1.6B
  • Common Stock · 9.4% · $172M
  • Other · 2.4% · $44M
  • US DOMESTIC · 1.0% · $19M
  • ADR · 0.5% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ISHARES TRNEW+108.6K108.6K+$1.6B$1.6B
SPDR S&P 500 ETF TRNEW+77.6K77.6K+$24M$24M
ESPRESPERION THERAPEUTICS INC NENEW+183.2K183.2K+$9M$9M
MEDTRONIC PLCNEW+75.8K75.8K+$7M$7M
ICUIICU MED INCNEW+35.6K35.6K+$7M$7M
OCULOCULAR THERAPEUTIX INCNEW+755.3K755.3K+$6M$6M
ABBVABBVIE INCNEW+62.6K62.6K+$6M$6M
HMSYHMS HLDGS CORPNEW+161.9K161.9K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1OXFORD IMMUNOTEC GLOBAL PLCORD SHS1.00%$18M1.40M
2EVOLENT HEALTH INCNOTE 2.000%12/00.97%$18M20.16M
3SIBNSI BONE INChistory →COM0.65%$12M743.4K
4JNJJOHNSON & JOHNSONhistory →COM0.65%$12M83.9K
5CNCCENTENE CORP DELhistory →COM0.59%$11M170.1K
6ZTSZOETIS INChistory →CL A0.55%$10M73.2K
7ESPRESPERION THERAPEUTICS INC NECOM0.52%$9M183.2K
8EHCENCOMPASS HEALTH CORPCOM0.48%$9M141.2K
9ELVANTHEM INCCOM0.43%$8M30.0K
10MEDTRONIC PLCSHS0.38%$7M75.8K
11CICIGNA CORP NEWCOM0.37%$7M36.1K
12ICUIICU MED INCCOM0.36%$7M35.6K
13LABORATORY CORP AMER HLDGSCOM NEW0.35%$6M37.9K
14OCULOCULAR THERAPEUTIX INCCOM0.34%$6M755.3K
15ABBVABBVIE INCCOM0.34%$6M62.6K
16ZBHZIMMER BIOMET HOLDINGS INCCOM0.30%$5M46.0K
17TREURTRILLIUM THERAPEUTICS INCCOM NEW0.30%$5M677.8K
18HMSYHMS HLDGS CORPCOM0.29%$5M161.9K
19SNYSANOFISPONSORED ADR0.28%$5M99.9K
20SELECTA BIOSCIENCES INCCOM0.28%$5M1.78M
21ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.27%$5M483.1K
22HO1HOLOGIC INCCOM0.26%$5M81.8K
23PROTHENA CORP PLCSHS0.23%$4M403.8K
24HRCHILL ROM HLDGS INCCOM0.21%$4M35.6K
25IM8NINSMED INCCOM PAR $.010.21%$4M140.2K
26BSXBOSTON SCIENTIFIC CORPCOM0.20%$4M106.3K
27CALLIDITAS THERAPEUTICS ABSPONSERED ADS0.20%$4M160.2K
28BAXBAXTER INTL INCCOM0.20%$4M42.4K
298INSYNEOS HEALTH INCCL A0.17%$3M54.6K
30MOLECULAR TEMPLATES INCCOM0.17%$3M229.8K
31ACRSACLARIS THERAPEUTICS INCCOM0.15%$3M1.73M
32HAEHAEMONETICS CORPCOM0.14%$3M28.9K
33MCKMCKESSON CORPCOM0.13%$2M15.9K
34MBIOUSDMUSTANG BIO INCCOM0.13%$2M768.5K
35UHSUNIVERSAL HLTH SVCS INCCL B0.12%$2M24.2K
36IQVIQVIA HLDGS INCCOM0.12%$2M15.8K
37BMYBRISTOL-MYERS SQUIBB COCOM0.12%$2M36.1K
38FATEFATE THERAPEUTICS INCCOM0.11%$2M60.9K
39PRNBPRINCIPIA BIOPHARMA INCCOM0.10%$2M30.4K
40BUWABIO RAD LABS INCCL A0.09%$2M3.5K
41XRAYDENTSPLY SIRONA INCCOM0.08%$2M35.1K
42BDXBECTON DICKINSON & COCOM0.08%$1M6.1K
43FPRXFIVE PRIME THERAPEUTICS INCCOM0.08%$1M237.2K
44SENSEONICS HLDGS INCNOTE 5.250% 2/00.07%$1M1.50M
45SUTRO BIOPHARMA INCCOM0.07%$1M156.0K
46AHCOADAPTHEALTH CORPCOM CL A0.06%$1M71.0K
47PTCTPTC THERAPEUTICS INCCOM0.05%$998,00019.7K
48ZGNXEURZOGENIX INCCOM NEW0.04%$799,00029.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.